Rheumatoid Arthritis Diagnostic Tests Market Report Scope & Overview:

The Rheumatoid Arthritis Diagnostic Tests Market was valued at USD 2.71 Billion in 2025 and is expected to reach USD 5.45 Billion by 2035, growing at a CAGR of 7.24% from 2026-2035.

The Rheumatoid Arthritis Diagnostic Tests Market is set to grow as rheumatoid arthritis increases in prevalence around the world, due to emphasis on early detection for preventing joint destruction and increased adoption of tests for anti-CCP and rheumatoid factor. Diagnosis is shifting from being based on the presence of one marker towards multi-biomarker diagnostic panels consisting of anti-CCP, RF, 14-3-3eta, and anti-RA33 antibodies. Automation of chemiluminescence and multiplex technologies is increasing lab efficiencies and accuracy. Molecular diagnostics for predicting patient response to biologics will provide new opportunities within the treatment of rheumatoid arthritis.

In November 2025, Augurex Life Sciences announced the launch of its 14-3-3eta rheumatoid arthritis test through Sonic Reference Laboratory, a division of Sonic Healthcare USA, beginning December 15, 2025. The test, approved as JOINTstat in Canada and the UK, supports earlier diagnosis and improved disease monitoring across Sonic’s U.S. network.

To Get More Information On Rheumatoid Arthritis Diagnostic Tests Market - Request Free Sample Report

Rheumatoid Arthritis Diagnostic Tests Market Trends:

• Rising adoption of multi-biomarker panels to diagnose seronegative and early-stage RA.

• Growing use of novel markers such as 14-3-3eta, anti-RA33, and anti-PAD4 antibodies.

• Increasing automation of anti-CCP and RF testing on chemiluminescence analyzers.

• Expanding use of molecular tests to predict response to anti-TNF biologic therapy.

• Growing application of AI and real-world data to assess treatment response in RA.

• Rising availability of RA testing through national reference laboratory networks.

U.S. Rheumatoid Arthritis Diagnostic Tests Market Outlook:

The U.S. Rheumatoid Arthritis Diagnostic Tests Market was valued at USD 0.96 Billion in 2025 and is expected to reach USD 1.87 Billion by 2035, growing at a CAGR of 6.87% from 2026-2035.

The U.S. Rheumatoid Arthritis Diagnostic Tests Market is expanding owing to the large patient population living with rheumatoid arthritis, estimated at about 1.3 million Americans, and strong awareness among physicians about the value of early diagnosis. The guidelines of American College of Rheumatology support the role of anti-CCP and RF test as an important part of classification criteria, thus contributing to uniform testing volume. The U.S. is home to several prominent reference laboratories including Quest Diagnostics, Labcorp, and Sonic Healthcare USA, besides autoimmune testing companies like Exagen and Scipher Medicine. Coverage for existing serological tests, along with biomarkers panels, will fuel the market expansion.

In January 2025, Exagen received conditional approval from the New York State Department of Health for new rheumatoid arthritis biomarkers and launched them on its AVISE CTD platform. The new RA profile adds anti-RA33 IgA, IgG, and IgM markers, helping clinicians confidently identify patients and support a seronegative RA diagnosis.

Rheumatoid Arthritis Diagnostic Tests Market Segment Analysis:

• By Test Type, the Anti-CCP segment dominated the Rheumatoid Arthritis Diagnostic Tests Market with approximately 27.64% share in 2025, while the Multi-Biomarker Panels segment is the fastest growing with a CAGR of approximately 9.42%.

• By Technology, the ELISA segment dominated the Rheumatoid Arthritis Diagnostic Tests Market with approximately 36.18% share in 2025, while the Chemiluminescence Immunoassay segment is the fastest growing with a CAGR of approximately 8.71%.

• By End User, the Diagnostic Laboratories segment dominated the Rheumatoid Arthritis Diagnostic Tests Market with approximately 47.53% share in 2025, while the Specialty Rheumatology Clinics segment is the fastest growing with a CAGR of approximately 8.36%.

By Test Type, Anti-CCP Leads, While Multi-Biomarker Panels Grow Fastest

The anti-CCP segment dominated the Rheumatoid Arthritis Diagnostic Tests Market in 2025, the most specific biomarker of RA is antibodies against cyclic citrullinated peptide (anti-CCP antibodies), with the specificity being 95 percent or more. Interestingly, anti-CCP antibodies can be detected several years before the symptoms begin, which allows identifying patients in advance and providing them with treatment prior to any joint destruction. Anti-CCP testing was included in the 2010 classification criteria of ACR/EULAR, thus becoming an established part of the diagnostics procedure for RA. Thanks to the existence of automated tests by Thermo Fisher, Abbott, Siemens Healthineers, Roche, and Bio-Rad, anti-CCP test remains a widespread diagnostic tool.

Multi-biomarker panels are the fastest-growing test type, as clinicians increasingly need more information to diagnose patients who test negative for both anti-CCP and rheumatoid factor. About one-third of RA patients are seronegative, making diagnosis difficult with traditional tests alone. Panels such as Exagen’s AVISE CTD combine established markers with newer ones such as anti-RA33 and anti-PAD4, while tests including Augurex’s 14-3-3eta add further diagnostic value. These panels also help distinguish RA from lupus, Sjögren’s syndrome, and other autoimmune conditions with overlapping symptoms. Growing clinical evidence and improving reimbursement are expected to drive strong adoption of multi-biomarker testing throughout the forecast period.

By Technology, ELISA Leads, While Chemiluminescence Grows Fastest

The ELISA segment dominated the Rheumatoid Arthritis Diagnostic Tests Market in 2025, ELISAs still represent one of the most commonly used methods in anti-CCP and rheumatoid factor as well as other autoantibodies detection. ELISA systems ensure high sensitivity and specificity, low price, and applicability to conventional laboratory equipment, which contributes to the popularity of these tests in medium-size laboratories and in developing countries. Among the leading providers, EUROIMMUN, Svar Life Science, Bio-Rad, and Tulip Diagnostics offer wide ranges of ELISA systems for autoimmune tests. Due to the extensive experience in use of this technology, its leading status continues to be maintained despite gradual replacement by automated systems.

Chemiluminescence immunoassay is the fastest-growing technology, with more and more laboratories turning towards fully automated systems that provide quicker analyses with greater efficiency than ELISA procedures, CLIA systems feature broad measurement ranges and high precision. Thus, anti-CCP, RF and other autoimmune tests can be conducted along with regular immunoassay tests on one system. Major manufacturers such as Abbott, Siemens Healthineers, Roche, Werfen, and Snibe are constantly widening their autoimmune test menus using automated analyzers. Increased test volumes, insufficient staff, and the merging of hospitals and reference laboratories will most likely accelerate the spread of CLIA systems for RA testing globally.

By End User, Diagnostic Laboratories Lead, While Rheumatology Clinics Grow Fastest

The diagnostic laboratories segment dominated the Rheumatoid Arthritis Diagnostic Tests Market in 2025, as independent and reference laboratories process the majority of serology tests ordered by primary care physicians and rheumatologists. Large laboratory networks such as Quest Diagnostics, Labcorp, and Sonic Healthcare operate high-volume automated platforms that offer broad test menus at competitive prices. These laboratories also serve as launch partners for new biomarkers, as shown by Sonic Reference Laboratory’s adoption of the 14-3-3eta test. Their extensive physician networks, strong payer contracts, and ability to offer specialized autoimmune panels continue to support the segment’s leading share throughout the forecast period.

Specialty rheumatology clinics are the fastest-growing end user segment, supported by the growing number of rheumatology practices, rising patient referrals, and increasing use of in-office testing to speed up diagnosis and treatment decisions. Many clinics now order advanced biomarker panels and treatment response tests, such as Scipher Medicine’s PrismRA, to guide the choice of biologic therapies. Integrated rheumatology networks are expanding their in-house laboratory and infusion services to improve care coordination and patient convenience. The shortage of rheumatologists in many regions is also encouraging the use of more accurate tests to reduce diagnostic delays, further supporting strong growth in this segment.

Regional Analysis:

North America Rheumatoid Arthritis Diagnostic Tests Market Insights

North America represented the biggest market share for the Rheumatoid Arthritis Diagnostic Tests Market with around 40.86% in 2025 owing to high disease awareness, high autoimmune test reimbursements and presence of well-established laboratory network in the region. Leading revenue generators in this region include United States where prominent players like Quest Diagnostics, Labcorp, Exagen, Scipher Medicine, and Sonic Healthcare USA offer their services. The guidelines provided by American College of Rheumatology emphasize early and accurate diagnosis and hence recommend routine anti-CCP and RF testings. North America is the leading region worldwide for advanced diagnostics of RA due to quick acceptance of novel biomarkers and multi-biomarker panels.

Canada holds a stable position in this market on account of provincial health care funding, rheumatology centers and early adoption of the 14-3-3eta test which is also called as JOINTstat in this country. Augurex Life Sciences, headquartered in Vancouver, Canada, is continuing to increase access to its test through laboratory partnerships. Mexico has smaller but growing market on account of growing number of private hospital and laboratory networks offering access to autoimmune testing and awareness of rheumatoid arthritis. The increasing utilization of electronic health record and clinical decision support is encouraging physicians to order right testings in time. However, pressure on laboratory reimbursement rate is an issue for the test providers in the region.

Get Customized Report as Per Your Business Requirement - Enquiry Now

Europe Rheumatoid Arthritis Diagnostic Tests Market Insights

Europe continues to be the second-largest regional market, supported by Germany, the UK, France, Italy, and Spain, where universal healthcare coverage and strong rheumatology networks ensure broad access to RA testing. The region is home to leading autoimmune diagnostics companies such as EUROIMMUN in Germany, Werfen in Spain, Svar Life Science in Sweden, and Roche in Switzerland. EULAR recommendations for early diagnosis and treat-to-target strategies encourage routine use of anti-CCP and RF testing. Early arthritis clinics in several countries are also increasing testing rates. The European In Vitro Diagnostic Regulation has raised evidence requirements, favoring suppliers with strong clinical data.

Germany dominates the market in the region, aided by its large number of laboratories, high volume of tests being conducted, and the active involvement of diagnostic companies. In the UK, the availability of special rheumatology services is growing because of NHS early inflammatory arthritis pathways and the approval of JOINTstat. France and Italy can rely on the developed hospital laboratory network and increased use of immunoassay automation. Spain contributes to market development with Werfen’s autoimmune diagnostics portfolio and hospital automation. The growing frequency of rheumatoid arthritis in the elderly keeps increasing testing demand in the region. However, at the same time, various cost-saving efforts impact prices in some European countries negatively.

Asia-Pacific Rheumatoid Arthritis Diagnostic Tests Market Insights

Asia-Pacific is currently witnessing the highest growth rate in the Rheumatoid Arthritis Diagnostic Tests Market, anticipated to record a CAGR of around 8.63% during the forecast period from 2026 to 2035, due to its large population, rising awareness of autoimmune diseases, and rapid expansion of laboratory infrastructure. China is the largest market in the region, driven by a large RA patient population, growing numbers of rheumatology departments, and strong domestic diagnostic manufacturers offering chemiluminescence platforms. Government efforts to expand hospital laboratory capacity and improve access to specialist care are increasing testing volumes across urban and county-level hospitals throughout the country.

Japan continues to be an important market, driven by its aging demographics, health insurance coverage for all residents, and frequent anti-CCP tests performed during routine clinical procedures. India is becoming increasingly important for growth due to a sizable base of undetected patients, an increasing number of private chains of diagnostic facilities, and local suppliers including Tulip Diagnostics, which supplies cost-effective test kits. South Korea capitalizes on advanced laboratory automation and the provision of point-of-care immunoassay systems by companies like Boditech Med. Australia drives growth through effective rheumatology care and reference laboratories. With increased availability of specialized care facilities in Southeast Asia, growth of the market in the region is expected to rise further over the forecast period.

MEA & Latin America Rheumatoid Arthritis Diagnostic Tests Market Insights

The Middle East & Africa region represents a smaller but growing share of the Rheumatoid Arthritis Diagnostic Tests Market, led by Gulf Cooperation Council states such as Saudi Arabia and the UAE, which are investing in modern hospital laboratories and specialized rheumatology services. Rising awareness of autoimmune diseases, expanding health insurance coverage, and government healthcare transformation programs are increasing access to advanced diagnostic testing. International laboratory operators and diagnostic companies are also strengthening their presence in the region. South Africa anchors demand across the wider African continent through its private healthcare sector, although limited laboratory infrastructure restricts testing in many other countries.

Latin America has recorded solid growths driven by Brazil with its high population, robust public healthcare system, and highly developed network of private labs conducting diagnostics. Mexico and Argentina are also generating high demands due to the development of hospital labs and increasing number of rheumatologists. Colombia is another market in Latin America, which is becoming an important one in terms of providing precision tests for RA thanks to the collaboration between Scipher Medicine and Grupo Amarey that will deliver PrismRA to Colombia, Panama, and Costa Rica. The rising knowledge about the need for early diagnosis contributes to the higher popularity of anti-CCP testing. However, limited public budgets restrict rapid development of the market.

Market Dynamics:

Growth Drivers: Rising RA Prevalence and Focus on Early Diagnosis

Growth in the Rheumatoid Arthritis Diagnostic Tests Market is primarily attributed to the rising global prevalence of rheumatoid arthritis, which affects nearly 18 million people worldwide according to global health estimates. The disease is more common in women and older adults, and aging populations are steadily increasing the number of people at risk. Early diagnosis is critical, as joint damage can begin within the first two years of disease onset. Clinical guidelines from the ACR and EULAR recommend prompt testing and early treatment to achieve remission, encouraging physicians to order anti-CCP, RF, ESR, and CRP tests at the first sign of symptoms.

Rapid technological advancements in the field of diagnosis are contributing to the growth of the market due to the discovery of novel biomarkers as well as new techniques in the automation of the process, which increases its accuracy and effectiveness. New biomarkers, including 14-3-3eta, anti-RA33, and anti-PAD4 allow diagnosing seronegative patients, who would not be detected by the regular diagnostics. In addition, automation of the process through the use of chemiluminescence and multiplex analyzers helps laboratories handle the rising test volume. Molecular tests predicting the effect of the biologic drugs treatment, such as PrismRA, create a novel category in the market.

Restraints: Diagnostic Complexity and Reimbursement Pressure

The complexity and variability of rheumatoid arthritis symptoms remain a key factor limiting market growth. Early RA can resemble other autoimmune and rheumatic diseases such as lupus, psoriatic arthritis, and Sjögren’s syndrome, making accurate diagnosis difficult. No single test can confirm RA, and about one-third of patients are seronegative for both anti-CCP and rheumatoid factor. Rheumatoid factor can also appear in healthy older adults and people with other conditions, leading to false-positive results. These challenges require clinicians to combine laboratory tests with physical examination and imaging, which can delay diagnosis and limit the standalone clinical value of individual laboratory tests.

Cost-related concerns will continue to act as a hindrance since reimbursement policies of both the U.S. and European nations have decreased costs for basic lab tests. The reduced costs on account of the U.S. Clinical Laboratory Fee Schedule and the cost containment programs of European healthcare systems are bound to affect not only labs but also makers of these tests. Even though there is considerable evidence for newer biomarkers and combination tests, they are covered at times which makes their adoption difficult. There are regulatory challenges such as that of the European In-Vitro Diagnostic Regulation, which delay the process and are expensive.

Opportunities: Novel Biomarkers and Precision Rheumatology

The development of novel biomarkers creates a significant opportunity for manufacturers and laboratories, as clinicians need better tools to diagnose seronegative RA and distinguish it from similar conditions. Markers such as 14-3-3eta, anti-RA33, anti-PAD4, and anti-carbamylated protein antibodies are gaining clinical acceptance and being added to multi-biomarker panels. Partnerships between biomarker developers and national reference laboratories, such as Augurex’s agreement with Sonic Reference Laboratory, are expanding access quickly. Companies that generate strong clinical evidence and secure reimbursement for novel markers can clearly differentiate their product offerings and steadily capture higher-value testing volumes across hospital laboratories and specialty rheumatology practices worldwide.

At the same time, the growing focus on precision rheumatology provides a major growth opportunity. Only about one-third of patients respond well to their first biologic therapy, and molecular tests that predict treatment response can help avoid costly trial-and-error prescribing. Tests such as PrismRA, combined with AI-driven tools that measure treatment response, can support payers’ efforts to control spending on biologic drugs. Rapid expansion of laboratory infrastructure in Asia-Pacific, Latin America, and the Middle East is also creating new demand for automated RA testing. Companies that combine diagnostic, monitoring, and data solutions are well positioned to capture a larger share of this growing market.

Recent Developments:

• 2025, Scipher Medicine unveiled an AI-driven RA Response Calculator at EULAR 2025, using real-world patient data to assess treatment response more accurately than CDAI and ACR scores.

• 2023, QIAGEN and Helix formed a global strategic agreement to develop companion diagnostics, combining Helix’s U.S. laboratory platform with QIAGEN’s QIAseq Human Exome Kits.

Rheumatoid Arthritis Diagnostic Tests Market Key Players:

• Abbott Laboratories

• Siemens Healthineers AG

• Thermo Fisher Scientific Inc.

• F. Hoffmann-La Roche Ltd.

• Danaher Corporation (Beckman Coulter)

• Bio-Rad Laboratories, Inc.

• Exagen Inc.

• Augurex Life Sciences Corp.

• Werfen

• Revvity, Inc. (EUROIMMUN)

• Svar Life Science AB

• Quest Diagnostics Incorporated

• Labcorp Holdings Inc.

• Sonic Healthcare Limited

• Scipher Medicine Corporation

• Boditech Med Inc.

• Tulip Diagnostics (P) Ltd.

• Trinity Biotech plc

• DiaSorin S.p.A.

• QIAGEN N.V.

Rheumatoid Arthritis Diagnostic Tests Market Report Scope: